Mucinous ovarian carcinoma (mEOC) represents a rare subtype of epithelial ovarian cancer, accounting for 3-4% of all ovarian carcinomas. The rarity of this tumor type renders both the preclinical and clinical research compelling. Very few preclinical in vitro and in vivo models exist. We here report the molecular, metabolic and pharmacological characterization of two patient derived xenografts (PDXs) from mEOC, recently obtained in our laboratory. These PDXs maintain the histological and molecular characteristics of the patient's tumors they derived from, including a wild type TP53. Gene expression analysis and metabolomics profile suggest that they differ from high grade serous/endometrioid ovarian carcinoma PDXs. The pharmacological characterization was undertaken testing the in vivo antitumor activity of both cytotoxic agents (cisplatin, paclitaxel, yondelis, oxaliplatin and 5-fluorouracile) and targeted agents (bevacizumab and lapatinib). These newly established mucinous PDXs do recapitulate mEOC and will be of value in the preclinical development of possible new therapeutic strategies for this tumor type.
Keywords: Patient-derived xenografts; chemotherapy; mucinous ovarian cancer.
AJCR Copyright © 2020.
Conflict of interest statement
Mucinous epithelial ovarian carcinoma.Ann Oncol. 2016 Apr;27 Suppl 1:i53-i57. doi: 10.1093/annonc/mdw087. Ann Oncol. 2016. PMID: 27141073 Review.
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.Pathology. 2011 Aug;43(5):420-32. doi: 10.1097/PAT.0b013e328348a6e7. Pathology. 2011. PMID: 21716157 Review.
TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.Exp Mol Pathol. 2013 Oct;95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004. Epub 2013 Aug 18. Exp Mol Pathol. 2013. PMID: 23965232
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies.Cancer Res Treat. 2017 Oct;49(4):915-926. doi: 10.4143/crt.2016.322. Epub 2017 Jan 4. Cancer Res Treat. 2017. PMID: 28052650 Free PMC article.
Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.Oncology (Williston Park). 2016 Feb;30(2):166-76. Oncology (Williston Park). 2016. PMID: 26892153 Review.